Can-Fite BioPharma (CANF) Accounts Payables (2013 - 2025)
Can-Fite BioPharma's (CANF) quarterly Accounts Payables came in at $1.2 million in Q4 2025, up 87.86% YoY from $618000.0 in Q4 2024, and up 0.78% on a QoQ basis from $1.2 million in Q2 2025.
Can-Fite BioPharma (CANF) Accounts Payables (2013 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 13 years of Accounts Payables data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Accounts Payables rose 87.86% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (up 87.86% YoY) and the FY2025 annual result came in at $1.2 million, up 87.86% from the prior year.
- Accounts Payables improved to $1.2 million in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.5 million in Q3 2022 to a low of $290000.0 in Q1 2021.
- A 5-year average of $877125.0 and a median of $890500.0 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables jumped 287.59% — and 2023, when it slumped 56.05%.
- Tracing CANF's Accounts Payables over 5 years: stood at $954000.0 in 2021, then decreased by 6.08% to $896000.0 in 2022, then tumbled by 52.34% to $427000.0 in 2023, then surged by 44.73% to $618000.0 in 2024, then soared by 87.86% to $1.2 million in 2025.
- The last three Accounts Payables figures came in at $1.2 million (Q4 2025), $1.2 million (Q2 2025), and $618000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Dec 31, 2024 | 618,000.00 |
| Jun 30, 2024 | 885,000.00 |
| Dec 31, 2023 | 427,000.00 |
| Sep 30, 2023 | 647,000.00 |
| Jun 30, 2023 | 810,000.00 |
| Mar 31, 2023 | 963,000.00 |
| Dec 31, 2022 | 896,000.00 |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 824,000.00 |
| Mar 31, 2022 | 1.12 Mn |
| Dec 31, 2021 | 954,000.00 |
| Sep 30, 2021 | 806,000.00 |
| Jun 30, 2021 | 1.01 Mn |
| Mar 31, 2021 | 290,000.00 |
| Dec 31, 2020 | 561,000.00 |
| Sep 30, 2020 | 784,000.00 |
| Jun 30, 2020 | 437,000.00 |
| Dec 31, 2019 | 2.16 Mn |